Figure 3From: Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors a. Progression-free survival after chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in patients with the EGFR mutation. b. Progression-free survival after chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in patients without the EGFR mutation.Back to article page